Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Allografting

Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute

Abstract

EBV-induced post transplant lymphoproliferative disorder (PTLD) continues to be a major complication after transplantation. Between January 1993 and April 2006, 12 cases of B-cell lymphoproliferative disorder were identified among 577 patients after allogeneic hematopoietic SCT (HSCT) with an overall incidence of 2.51% at 1 year. Grades II–IV acute GVHD, CMV antigenemia and the use of antithymocyte globulin (ATG) were independent risk factors for PTLD. At diagnosis, all of the tumors were CD20-positive and 11 (92%) were EBV-encoded RNA (EBER)-positive. Of the 12 patients with B-cell lymphoproliferative disorder, 8 had pulmonary involvement and 10 had extranodal involvement. Eleven patients received weekly rituximab therapy at a dose of 375 mg/m2; the median interval between the onset of symptoms and rituximab therapy was 6 days. The overall mortality rate was 92% and seven (64%) of the deaths were directly attributable to disseminated PTLD within days or weeks of presentation. In our series, pulmonary PTLD followed an extremely aggressive course and poor response to current therapy, even though rituximab was included in the therapeutic regimens.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A–prednisone immunosuppression. Am J Pathol 1988; 133: 173–192.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Cohen JI . Epstein–Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991; 70: 137–160.

    Article  CAS  Google Scholar 

  3. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL . Epstein–Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461–472.

    Article  CAS  PubMed  Google Scholar 

  4. Blazar B, Patarroyo M, Klein E, Klein G . Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein–Barr viral cycle by superinfection or sodium butyrate. J Exp Med 1980; 151: 614–627.

    Article  CAS  PubMed  Google Scholar 

  5. Pearson GR, Orr TW . Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein–Barr virus antigens. J Natl Cancer Inst 1976; 56: 485–488.

    Article  CAS  PubMed  Google Scholar 

  6. Wallace LE, Rickinson AB, Rowe M, Epstein MA . Epstein–Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 1982; 297: 413–415.

    Article  CAS  PubMed  Google Scholar 

  7. Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251–258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR et al. Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234–1243.

    CAS  PubMed  Google Scholar 

  9. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784–789.

    Article  CAS  PubMed  Google Scholar 

  10. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED et al. Epstein–Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529.

    CAS  PubMed  Google Scholar 

  11. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.

    CAS  PubMed  Google Scholar 

  12. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552–565.

    CAS  PubMed  Google Scholar 

  13. d'Amore ES, Manivel JC, Gajl-Peczalska KJ, Litz CE, Copenhaver CM, Shapiro RS et al. B-cell lymphoproliferative disorders after bone marrow transplant. An analysis of ten cases with emphasis on Epstein–Barr virus detection by in situ hybridization. Cancer 1991; 68: 1285–1295.

    Article  CAS  PubMed  Google Scholar 

  14. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.

    CAS  PubMed  Google Scholar 

  15. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.

    Article  CAS  PubMed  Google Scholar 

  16. Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229–239.

    Article  PubMed  Google Scholar 

  17. Deeg HJ, Socie G . Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833–1844.

    CAS  PubMed  Google Scholar 

  18. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G et al. Epstein–Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517–1525.

    Article  CAS  PubMed  Google Scholar 

  19. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583–587.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112–118.

    Article  CAS  PubMed  Google Scholar 

  21. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113–116.

    Article  PubMed  Google Scholar 

  22. Straathof KC, Savoldo B, Heslop HE, Rooney CM . Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002; 118: 728–740.

    Article  PubMed  Google Scholar 

  23. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569–576.

    Article  CAS  PubMed  Google Scholar 

  24. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053–3057.

    Article  CAS  PubMed  Google Scholar 

  25. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901–2906.

    Article  CAS  PubMed  Google Scholar 

  26. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137–3147.

    CAS  PubMed  Google Scholar 

  27. Hoshino Y, Kimura H, Kuzushima K, Tsurumi T, Nemoto K, Kikuta A et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein–Barr viral load. Bone Marrow Transplant 2000; 26: 199–201.

    Article  CAS  PubMed  Google Scholar 

  28. Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224–233.

    Article  PubMed  Google Scholar 

  29. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE . Early identification of Epstein–Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98–103.

    Article  CAS  PubMed  Google Scholar 

  30. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH et al. Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165–1171.

    Article  CAS  PubMed  Google Scholar 

  31. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979–3981.

    Article  CAS  PubMed  Google Scholar 

  32. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807–814.

    CAS  PubMed  Google Scholar 

  33. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972–978.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Yao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hou, HA., Yao, M., Tang, JL. et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 43, 315–321 (2009). https://doi.org/10.1038/bmt.2008.325

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.325

Keywords

This article is cited by

Search

Quick links